The German giant has already trimmed more than 10,000 employees since initiating a massive restructuring initiative in July ...

Terns, once a rising star in obesity and the MASH space, will refocus on cancer and partner out a handful of obesity assets.

Maziar Mike Doustdar, who was named as Novo Nordisk’s new CEO last week, spoke on a second quarter earnings call of ...

The Department of Health and Human Services is terminating around $500 million in BARDA contracts associated with mRNA ...

President Donald Trump plans to start with a “small tariff” on pharmaceutical imports before ramping duties up to 250% within ...

BioNTech also laid off 63 employees in June in conjunction with the discontinuation of its cell therapy manufacturing ...

While a substantial portion of pipeline assets are externally sourced, many Big Pharmas are tapping into incubators and ...

George Tidmarsh takes over temporarily at CBER following Vinay Prasad’s abrupt departure; Replimmune trial leaders protest ...

The regulatory environment is placing extreme pricing pressure on pharmaceutical manufacturers. Their success in the market ...

Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is ...

Leslie Zhen Liang is an award-winning investigative health and science journalist with a decade of experience covering ...

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.